Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Executive Summary

Juno Therapeutics Inc. planned to win US FDA approval in 2017 for its chimeric antigen receptor T cell (CAR-T) cell therapy JCAR015, but the company has reached another significant milestone that may delay that goal: its Phase II ROCKET clinical trial in the treatment of adults with relapsed or refractory B cell acute lymphoblastic lymphoma (ALL) has been put on clinical hold due to three deaths.

Advertisement

Related Content

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again
New Interim CAR-T Data Support Kite’s BLA Submission Plans
INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve
Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
Uncertainty Looms For Ziopharm After Patient Death
ASH 2015: As CAR-T Players Vie For 1st Place, Will Efficacy Trump Safety?
Celgene shows CAR-T confidence with $1bn Juno investment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel